NFKB1 and Hodgkins lymphoma: A Comparison of the results of biomarker studies in pediatric HL patients indicates that NF-κB, sCD30, and ICAM-1, are most likely to be independent prognostic markers for clinical outcome predictions (Table 2), although ICAM-1 requires validation with a larger cohort.